Back to Gene
FN1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

FN1 gene

The FN1 gene provides instructions for producing fibronectin-1, a protein essential for tissue repair, blood clotting, and the structural integrity of the extracellular matrix.

Normal Function

The FN1 gene provides instructions for making two types of the fibronectin-1 protein: soluble plasma fibronectin-1 and insoluble cellular fibronectin-1. Liver cells produce soluble plasma fibronectin-1 and release it into the bloodstream, where it is mainly involved in blood clotting and wound healing. Soluble plasma fibronectin-1 functions outside of cells (in the extracellular spaces), attaching (binding) to the surface of cells and binding to proteins, including other fibronectin-1 proteins. The attachment of these proteins form fibers that assist with tissue repair after an injury.

Fibronectin-1 binding also helps with the continual formation of the extracellular matrix, which is an intricate lattice of proteins and other molecules that is made in the spaces between cells. This matrix provides structure and strength to tissues that support the body's organs. Many other cell types produce insoluble cellular fibronectin-1, which is released into the extracellular space and contributes to the creation of fibers and extracellular matrix. Both types of fibronectin-1 help individual cells expand (spread) and move (migrate) to cover more space and also influence cell shape and maturation (differentiation).

Health Conditions Related to Genetic Changes

Fibronectin glomerulopathy

At least three mutations in the FN1 gene have been found to cause fibronectin glomerulopathy, a progressive kidney disease that usually begins in adulthood and results in irreversible kidney failure (end-stage renal disease). FN1 gene mutations account for about 40 percent of cases of fibronectin glomerulopathy.

The FN1 gene mutations change single protein building blocks (amino acids) in the fibronectin-1 protein. One mutation that occurs in multiple families replaces the amino acid tyrosine with the amino acid cysteine at position 973 in the fibronectin-1 protein (written as Tyr973Cys or Y973C). These mutations impair the protein's ability to bind to cells and proteins.

The unbound fibronectin-1 protein, specifically soluble plasma fibronectin-1, is deposited in the glomeruli of the kidneys. These structures are clusters of tiny blood vessels in the kidneys that filter waste products from blood. Even though there is an abundance of fibronectin-1 in the glomeruli, the extracellular matrix that supports the blood vessels is weak because the altered fibronectin-1 cannot assist in the matrix's continual formation. Without a strong cellular support network, the glomeruli are less able to filter waste, leading to the following issues:

  • Protein and blood are released in the urine.
  • Acids are not properly filtered from the blood.
  • Kidney function decreases over time, resulting in end-stage renal disease.

Frequently Asked Questions

Yes. Maintaining a low‑protein diet (0.8–1.0 g/kg/day), controlling blood pressure with ACE inhibitors or ARBs, limiting sodium to <2 g/day, and avoiding nephrotoxic drugs (NSAIDs, certain antibiotics) can help preserve kidney function. Regular monitoring of blood pressure, weight, and kidney labs is crucial.
Early signs include painless proteinuria, mild edema, or a gradual rise in serum creatinine. Some patients notice blood in urine or fatigue. If a family member has the mutation, routine urinalysis every 6–12 months can catch early changes.
Diagnosis requires a kidney biopsy showing fibronectin deposits in the glomeruli, confirmed by immunofluorescence staining for fibronectin. Blood tests for kidney function (creatinine, eGFR), urinalysis for protein, and genetic testing for FN1 mutations are also essential.
Research is exploring antifibrotic agents, such as pirfenidone, and gene‑silencing approaches (siRNA) to reduce fibronectin production. Patients can search clinicaltrials.gov for trials involving fibronectin glomerulopathy or discuss potential enrollment with a nephrologist.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA